Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159
What this trial is testing
Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Who this might be right for
Early Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer
Fujian Cancer Hospital 200